Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Corey Stephen Cutler, M.D.

Co-Author

This page shows the publications co-authored by Corey Cutler and Zachariah DeFilipp.
Connection Strength

2.616
  1. A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation. Bone Marrow Transplant. 2020 04; 55(4):804-810.
    View in: PubMed
    Score: 0.883
  2. Belumosudil for Chronic Graft-versus-Host Disease (cGVHD) After 2 or More Prior Lines of Therapy: The ROCKstar Study. Blood. 2021 Jul 15.
    View in: PubMed
    Score: 0.249
  3. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. Transplant Cell Ther. 2021 Jun 11.
    View in: PubMed
    Score: 0.248
  4. Correction: Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. Bone Marrow Transplant. 2021 May; 56(5):1217.
    View in: PubMed
    Score: 0.246
  5. Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. Bone Marrow Transplant. 2021 05; 56(5):1006-1012.
    View in: PubMed
    Score: 0.235
  6. Endogenous thrombopoietin levels are elevated following double cord blood unit transplantation. Bone Marrow Transplant. 2020 06; 55(6):1178-1180.
    View in: PubMed
    Score: 0.219
  7. Phase 1 study of the Hedgehog pathway inhibitor sonidegib for steroid-refractory chronic graft-versus-host disease. Blood Adv. 2017 Oct 10; 1(22):1919-1922.
    View in: PubMed
    Score: 0.192
  8. Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021 May 20.
    View in: PubMed
    Score: 0.062
  9. Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021 Apr 16.
    View in: PubMed
    Score: 0.061
  10. Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2021 06; 27(6):479.e1-479.e7.
    View in: PubMed
    Score: 0.061
  11. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Adv. 2020 07 14; 4(13):3180-3190.
    View in: PubMed
    Score: 0.058
  12. Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv. 2020 05 12; 4(9):1965-1973.
    View in: PubMed
    Score: 0.057
  13. Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes. Biol Blood Marrow Transplant. 2017 Jun; 23(6):971-979.
    View in: PubMed
    Score: 0.046
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.